Improving profitability in the dispensing pharmacy business through tighter cost management
First written in FY2018-Q2. 9 of 15 entries say "Restated". Latest entry: FY2027-H1.
The whole theme swung hardest in 2022: 4 of 11 companies on the "Worse" side.
0 other companies' latest entry also says "Restated".
- FY2027-H1RestatedAnnual report
「Accordingly, while promoting business expansion and operational efficiency, the company is working to strengthen its earnings base.」
In response to the business characteristics of an industry based primarily on regulated prices, the company continues to pursue business expansion, operational efficiency and strengthening its earnings base. - FY2026RestatedAnnual report
「The Group will realise the integration benefits of businesses expanded through M&A and other means at an early stage, promote operational efficiency and reduce costs and selling, general and administrative expenses, while expanding its business model by leveraging synergies among its 3 core businesses.」
The Group continues to strengthen earnings capacity through post-M&A integration benefits, operational efficiency improvements, reductions in costs and selling, general and administrative expenses, and the use of synergies among its 3 core businesses. - 2026-04-06AdvancedEarnings
「We will continue to expand our top line by leveraging M&A, enhance our internal structure, and build stable earnings power by realising integration benefits at an early stage.」
In addition to expanding revenue through M&A, the Group expressly identifies strengthening its internal structure and realising integration benefits early as means of building earnings power. - FY2025RestatedAnnual report
「② Strengthening earnings capacity through efficient management The Group will further improve management efficiency through the stronger group capabilities resulting from organisational restructuring, promote the systemisation of pharmacy operations and the standardisation of workflows, and focus on reducing the expense ratio of indirect functions.」
The Group continues to pursue efficient management through organisational restructuring, store systemisation, workflow standardisation, and a lower expense ratio for indirect functions. - FY2023RestatedAnnual report
「The Group pursued greater management efficiency through the merger of subsidiaries and focused on expanding community-coordinating pharmacies and pharmacies coordinating with specialist medical institutions, as well as addressing home healthcare.」
The Group continues to pursue greater management efficiency through the integration of subsidiaries, expand function-specific pharmacies, and address home healthcare. - FY2023-Q2AdvancedAnnual report
「In the dispensing pharmacy business, 株式会社メディカル一光, the core subsidiary, integrated its subsidiaries 株式会社山梨薬剤センター and 有限会社クローバー in March 2022, promoting the integration of business operations and greater management efficiency.」
The Group states that it advanced the integration of operations and management efficiency in the dispensing pharmacy business through the integration of subsidiaries in March 2022. - FY2023-Q1RestatedAnnual report
「Against this backdrop, the Group has pursued greater management efficiency through business restructuring and worked to contain expenses.」
The Group continues to improve profits in the dispensing pharmacy business through greater management efficiency and expense containment achieved through business restructuring. - FY2021-Q3RestatedAnnual report
「The Group worked to reduce various operating expenses in its pharmacy operations.」
In the dispensing pharmacy business, the Group continues to pursue greater efficiency and profit improvement by reducing various operating expenses. - FY2020-Q3RestatedAnnual report
「In the dispensing pharmacy business, revenue and profit increased due to higher revenue per prescription and the effects of expense reviews. As a result, revenue was ¥17,156 million, up 1.9% year on year, and operating profit was ¥1,036 million, up 0.9% year on year.」
The Group continues to improve profits through higher revenue per prescription and the effects of expense reviews, and the dispensing pharmacy business achieved higher revenue and profit. - FY2020-Q2RestatedAnnual report
「In the dispensing pharmacy business, revenue and profit increased due to higher revenue per prescription and the effects of expense reviews.」
The Group continues to cite profit improvement resulting from higher revenue per prescription and expense reviews. - FY2020-Q1AdvancedAnnual report
「In the dispensing pharmacy business, revenue declined because the number of prescriptions filled was lower than in the previous fiscal year, but profit increased due to the effects of higher revenue per prescription and expense reviews. As a result, revenue was ¥5,799 million, down 0.4% year on year, and operating profit was ¥398 million, up 18.1% year on year.」
Despite lower revenue due to a decline in the number of prescriptions filled, operating profit increased 18.1% year on year due to higher revenue per prescription and the effects of expense reviews. - FY2019RestatedAnnual report
「The Group will further improve management efficiency by capitalising on the stronger group capabilities resulting from organisational restructuring, promote the systemisation of pharmacy operations and the standardisation of workflows, and focus on reducing the expense ratio of indirect functions.」
The Group continues to pursue efficient management through organisational restructuring, store systemisation, workflow standardisation, and a lower expense ratio for indirect functions. - FY2018ReframedAnnual report
「Strengthening earnings capacity through efficient management The Group will further improve management efficiency by capitalising on the stronger group capabilities resulting from organisational restructuring, promote the systemisation of pharmacy operations and the standardisation of workflows, and focus on reducing the expense ratio of indirect functions.」
The description of the measures has been broadened from cost management in the dispensing pharmacy business to company-wide efficient management, including organisational restructuring, store systemisation, workflow standardisation, and a lower expense ratio for indirect functions. - FY2018-Q3AdvancedAnnual report
「As a result of efforts to strengthen cost management, operating profit increased to ¥1,311 million, up 16.8% year on year.」
The Group continues to strengthen cost management, and operating profit in the dispensing pharmacy business increased 16.8% year on year. - FY2018-Q2First statedAnnual report
「In the dispensing pharmacy business, revenue declined because the unit price of pharmaceutical products was below the previous fiscal year. Profit increased, however, as the company strengthened cost management. As a result, revenue was ¥11,242 million, down 1.1% year on year, and operating profit was ¥831 million, up 17.9% year on year.」
Tighter cost management was cited as a measure to address the decline in revenue caused by lower drug prices, and operating profit increased 17.9% year on year.